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 The preeminent ethical challenge to international research is the application of principles 
to biomedical research in a multicultural world, amidst a multiplicity of health-care systems and 
considerable variations in standards of health-care. Progress in medical care and disease 
prevention depends upon an understanding of physiological and pathological processes and 
epidemiological findings, and requires time researching human subjects. Before watershed 
events of the mid-1900s, international research with human subjects was infrequently carried out 
by, or strictly supervised by, investigators concerned with establishing informed consent or 
conducting thorough risk analyses.1 Ethical protocol was largely nonexistent in regards to the 
aims and conduct of both international and domestic research, and as a result, clinical 
participants were frequently ignorant of the nature and degree of even known risks of their 
participation.2  
The first international instrument on the ethics of medical research, the Nuremberg Code, 
was promulgated in 1947 as a consequence of the atrocious experiments on unconsenting 
prisoners and detainees during the Second World War.3 The Code, designed to protect the 
integrity of the research subject, set forth an ethical standard to be applied to research involving 
human subjects, emphasizing voluntary consent.4 Similarly, national clinical regulations were 
inspired by the respective demons of several countries with their own colorful histories of 
clinical discovery. The United States and the U.K., two of the most active nations conducting 
and funding international research, shaped clinical regulations in the shadow of public exposures 
of human rights violations revealed shortly after World War II.5 (e.g., The Tuskegee Syphilis 
                                                 
1
 Charles R. McCarthy. Historical Background of Clinical Trials Involving Women and Minorities 69 ACADEMIC 
MEDICINE 695, 695-96 (1994) (before the mid-1940s, clinical research was literally unreviewed; researchers could 
go abroad and escape all forms of regulatory scrutiny as to their methods or clinical development operations;); See 
also, James v. Lavery, Monitoring and Oversight in Critical Care Research, 8 CLINICAL CARE 403, 403-405 
(explaining that peer review of clinical research could have improved the ethical standards of the early 1900s despite 
a lack of regulatory overview, an absence which she claims allowed researchers to inject elderly indigent patients 
with live cancer cells in the early 1960s, and permitted an ethically dubious and unsuccessful chimpanzee-to-human 
kidney transplant at Tulane University in 1960.) 
2
 McCarthy, supra note 1, at 696.  
3
 Id. at 697. 
4
 11 Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law, 181-82 (1949) 
[hereinafter, The Nuremberg Code] (“[T]he voluntary consent of the human subject is absolutely essential. This 
means the person involved should have legal capacity to give consent; should be so situated as to be able to exercise 
free power of choice, without the intervention of any element of force, fraud, deceit, duress, over-reaching, or other 
ulterior form of constraint or coercion; and should have sufficient knowledge and comprehension of the elements of 
the subject matter involved as to enable him to make an understanding and enlightened decision.”)  
5
  See, e.g., Margaret Liu & Kate Davis, A CLINICAL DRUGS MANUAL FROM THE DUKE CLINICAL RESEARCH 
INSTITUTE. 320-343 (2nd. ed. 2010). (explaining that the aftermath of the Tuskegee study and the thalidomide 
tragedy of the 1950s led to the 1962 Kefauver-Harris Amendments in the U.S., which required proof that drugs are 
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 Study [1932–1972], Europe's drug tragedy with thalidomide [1960s], and the Holmesburg Prison 
testing program [until the early 1980s]).6 This history of research abuse raised the index of 
suspicion both among legislatures and amongst those in the research community, including 
potential participants. Their suspicions created incentives to bar minority research participation 
and generated a climate of proactive preclusion for formerly abused classes of study participants. 
 As a result, domestic and international regulations were drafted in such as way as to 
categorically preclude women from many forms of international clinical study. In the late 1970s, 
conservative regulations and guidelines issued by the United Kingdom’s Department of Health 
and the United State’s Food and Drug Administration (FDA) encouraged the exclusion of 
women of childbearing age from large-scale clinical trials, conducted both domestically and 
internationally. For example, FDA guidelines promulgated in 1977 advised that women of 
"childbearing potential" participate in trials only after Phase II (efficacy and safety) trials and 
(female) animal reproductive studies have been completed.7 The U.K adopted an almost identical 
policy for pregnant and pre-menopausal women.8  The U.S. and the U.K. were the earliest 
leading nations funding and organizing international research; therefore, these policies shaped 
global research models of scientific and ethical practice.9  
 This international protectionist and exclusionary policy proved to be fundamentally 
disruptive to the progression of women’s interests in health research. Because drug trials based 
clinical findings from results of tests using the male body, a form both physically and 
physiologically different from that of the female, drug therapies were inadequate for women.10 
                                                                                                                                                             
both safe and effective before marketing them and provided the basis for the current IND (Investigational New Drug 
application). Drug safety was not the subject of any legislation in the U.K. until after the thalidomide disaster, 
following which, the Committee on Safety of Drugs was set up in June 1963 by the Health Minister in consultation 
with the medical and pharmaceutical professions and the pharmaceutical industry. The Medicines Act of 1968 the 
replaced most of the previous legislation on the control of medicines for both human and veterinary use.)  
6
 See R.H. Kampmeier. The Tuskegee Study of Untreated Syphilis. 65 SOUTH MED J. 1243, 1247–51 (1972) 
(explaining that in the Tuskegee study, 412 poor African- American men with untreated syphilis were followed and 
studied even after penicillin, a cure for the disease, became available); Medicine: The Thalidomide Disaster. Time. 
Aug. 19, 1962, at 15 (describing the birth defects arising from thalidomide usage); Allen Hornblum, ACRES OF SKIN: 
HUMAN EXPERIMENTS AT HOLMESBURG PRISON 310 (1998) (describing the decades-long dermatological, 
pharmaceutical, and biochemical weapons research projects involving testing on inmates during the Holmesburg 
Prison testing program.) 
7
 Federal Policy for the Protection of Human Subjects. 45 C.F.R. §§ 46.101–124. (1991). 
8
 John Griffin, THE TEXTBOOK OF PHARMACEUTICAL MEDICINE. 318 (6th ed. 2009).  
9
 M.N. Prout. Participation of Women in Clinical Trials of Drugs Therapies: a Context for the Controversies. 3 MED 
GEN MED 60 (2001). 
10
 Vanessa Merton, The Exclusion of Pregnant, Pregnable, and Once-Pregnable People (a.k.a. Women) from 
Biomedical Research.13 AM. J OF LAW & MED. (1993). (Robert Levine succinctly laid out the dilemma that 
confronts women who need medical care: “It is the custom in the United States to develop new drugs based upon 
2
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 However, once therapies by a predominantly male sample became available in the marketplace, 
practitioners were free to offer the therapy to women without prior testing.11 As a result, women 
across the world were taking drugs without calibration for their specific physiological needs, and 
suffering from an absence in clinical research.12   
The protective clinical research, inattentive to injuries, conditions, and diseases that 
primarily threatened women’s lives, rendered physicians utterly ignorant as to how certain drugs 
affected the female body. The male-centered history of clinical discovery, built around the 
masculine form and developed primarily by men, led to inadequate therapies. The long-term 
damage of the approach, however, was its contribution to a systemic form of ethical clinical 
abuse: the development of a clinical model that failed to incorporate women’s experience in 
clinical trials.  
In this paper, I address the human rights issues that arise from the unethical treatment of 
women in clinical research worldwide. I develop first a background for the discourse, explaining 
the history of international human rights legislation specific to clinical research. I then explain 
how women became excluded from international clinical trials, emphasizing the role of the 
                                                                                                                                                             
testing of their safety and efficacy almost exclusively in adults who are incapable of becoming pregnant. . . . As a 
consequence, most drugs must contain on their . . . labels a statement to the effect that their safety and/or efficacy 
have not been established in children and/or pregnant women. In fact, it might be more appropriate to include in 
such statements that the safety and/or efficacy of the drug has not been established in women who are capable of 
becoming pregnant. . . .It is common practice in this country to administer drugs approved for use in non-pregnant 
adults to pregnant women and children. 
Such administration is conducted according to the usual standards of medical practice without rigorous testing of 
safety and/ or efficacy. In this way we have a tendency to distribute the unknown risks of such activities not 
randomly but rather capriciously. In addition, we have no assurance that, should the risks materialize as harm, they 
will be detected.”); Drug Testing on Men Only, WASH. POST, Dec. 8, 1992, at 214 (quoting Nancy Buc, former 
General Counsel at Food and Drug Administration, "For many if not most drugs on the market, no one really knows 
whether they behave any differently in women. Nobody really knows what their role is or should be in pregnancy.") 
11
 See Robert Walker, Heart Studies Ignore Women, CALAGHERY HERALD, Oct. 19, 1991, at B2 (report on 
presentations at the annual meeting of the Canadian Cardiovascular Association explaining historical administration 
of cardiomuscular and pulmonary therapies that were unsuited to the female physiology and pharmacology); 
Caroline Mallan, MDs Assume Men Need Better Care, TORONTO STAR, July 26, 1991, at A26 (Canadian men over 
the age of 45 more than twice as likely as women with similar heart disease to undergo diagnostic angiography and 
three times as likely to have bypass surgery; doctors don't offer heart surgery to women because they may believe 
that women don't need to return to work after heart attacks.) 
12
 See, Jeannette R. Ickovics & Judith Rodin, Women and AIDS in the United States - Epidemiology, Natural 
History, and Mediating Mechanisms, 11 HEALTH PSYCHOL. 110, 112 (1982) (although women represent more than 
one-third of all cases of AIDS globally and die significantly sooner after diagnosis than men with AIDS, and despite 
important gender differences in all phases of the disease process, women are still excluded from most biomedical 
and psychosocial research, and white males predominate in almost all clinical AIDS trials); Gina Kolata, AIDS 
Research on Drugs Bypasses Addicts and Women, N.Y. TIMES, Jan. 5, 1988, at C1, C7 (recounting the heroic, but 
unsuccessful, efforts of leading epidemiologist Dr. Zena Stein to get funding from NIH and the American 
Foundation for AIDS Research to study the disease in women.) 
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 regulations guiding the standards employed worldwide by researchers and clinical institutions. 
Then, I explain how this exclusion began to manifest as human rights abuses as women in 
clinical research faced challenges of informed consent and access struggles within the clinical 
model of drug development. Finally, I construct a model for ethical clinical research, building 
within the framework of leading international human rights doctrines, but incorporating theories 
used by biologist and human rights scholar H. Beaqueart and bio-ethicist Kaushik Sunder Rajan. 
In a case study, I apply this “feminist” model of clinical research. I use a renowned, large-scale 
clinical study to demonstrate that a clinical trail can legally adhere to international research 
regulations and ethically treat women according to the elements of a feminist model. Using the 
oral contraceptive research trials in Puerto Rico, conducted by American and English physicians, 
I demonstrate that international human rights legislation and feminist ethical concerns can 
operate alongside each other in a framework for a successful research endeavor.  
 
Historical Development of Human Rights in International Clinical Research 
 Clinical research has become a global enterprise. Investigators and sponsors must deal 
with multiple legal jurisdictions, with differing laws, regulations and other rules.13 (The term 
“law,” as used in this paper, includes both laws and regulations.) These rules establish 
expectations based on each party’s locale. As described below, public and non-profit entities also 
have various legal constraints. These rules limit the flexibility of investigators (i.e., research 
sites) when negotiating clinical trial agreements (CTAs).  
While the first international instrument on the ethics of medical research, the Nuremberg 
Code, was never officially adopted in its entirety as law by any nation or as ethics by any major 
medical association, its influence on global human-rights law and medical ethics has been 
profound.14 Its basic requirement of informed consent, for example, has been universally 
accepted and is articulated in international law in Article 7 of the United Nations International 
Covenant on Civil and Political Rights.15 Informed consent, with specific reliance on the 
                                                 
13
 Norman M. Goldfarb. Laws, Regulations, and Clinical Trial Agreements, Address at the Society of Research 
Administrators International 2004 Symposium. (2004) (explaining that for years, researchers have encountered 
different jurisdictions with differing rules. For example, when conducting research among the Member States of the 
European Union, researchers must follow the EU Clinical Trials Directive. In addition, they must adhere to 
additional and often more specific requirements on a state level. Spain, for example, requires different forms of 
consent in terms of minors than Italy does.)  
14
 See M.A. Grodin. Legacies of Nuremberg: Medical Ethics and Human Rights. 73 JAMA 1676:1682-1683 (2003).  
15
 The International Covenant on Civil and Political Rights. art. 7. U.N. Doc. A/6316 (Mar. 23, 1976) 
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 Nuremberg Code, is the basis of the International Ethical Guidelines for Biomedical Research 
Involving Human Subjects, the guidelines promulgated by the World Health Organization and 
the Council for International Organizations of Medical Sciences.16 The Code catalyzed a 
transnational effort to establish an ethical conduct of research involving human subjects, 
emphasizing informed and voluntary consent to research.17 
The Universal Declaration of Human Rights was adopted by the General Assembly of the 
United Nations in 1948.18 The General Assembly adopted the International Covenant on Civil 
and Political Rights in 1966 to give the Universal Declaration legal force. Its Article 7 states, 
‘‘No one shall be subjected to torture or to cruel, inhuman or degrading treatment or punishment. 
In particular, no one shall be subjected without his free consent to medical or scientific 
experimentation.’’19 The statement hallmarked the dramatic shift in governing rules of clinical 
work during the early twenty-first century: a sentiment that all research involving human 
subjects should strive to protect the rights and welfare of all human subjects of scientific 
experimentation.  
In 1964, the World Medical Association brought together physicians, lawyers, ethicists 
and researchers from global institutes and hospitals to establish recommendations respecting the 
Covenant’s legal principles. It compiled and issued The Declaration of Helsinki, a long and 
detailed doctrine defining rules for "research combined with clinical care" and "non-therapeutic 
research" performed internationally.20 Today, the Declaration of Helsinki reigns as the 
fundamental international document in the field of humans rights in biomedical research. The 
Declaration, amended most recently in 2008,21 sets comprehensive ethical guidelines for 
physicians engaged in both clinical and nonclinical biomedical research. The Declaration 
espouses three principles: beneficence, justice, and human dignity,22 which serve to foundate its 
                                                 
16
 Council for International Organizations of Medical Sciences, International Ethical Guidelines for Biomedical 
Research Involving Human Subjects. 2002. [herein after, Guidelines] 
17
  Anonymous. World Medical Association Declaration of Helsinki: Ethical principles for Medical Research 
Involving Human Subjects. J AM MED ASSOC, 40: 43–45 (2000). 
18
 Universal Declaration of Human Rights, G.A. Res. 217 (III) A, U.N. Doc. A/RES/217(III) (Dec. 10, 1948) 
[hereinafter the Declaration]; Johannes Morsink, THE UNIVERSAL DECLARATION OF HUMAN RIGHTS: ORIGINS, 
DRAFTING & INTENT 72 (1999). 
19
 supra note 17.  
20
 E.  Emanuel & C. Grady. The 2000 revision of the Declaration of Helsinki: A step forward or more confusion? 
LANCET, Sept. 30, 2001, at 149–53. 
21
 J.R Williams, The Declaration of Helsinki and public health. BULLETIN OF THE WORLD HEALTH ORGANIZATION 
2008, at 650-651. 
22
 supra note 18. 
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 ethical requirements. The Declaration, for example, mandates that research with humans be 
based on the results from laboratory and animal experimentation, that research protocols should 
be reviewed by an independent committee prior to initiation, that informed consent from research 
participants is necessary, that research should be conducted by medically/scientifically qualified 
individuals, and that the risks of any trial should not exceed benefits to its participants.23 Another 
recently added guideline is intended to provide absolute transparency regarding economic 
incentives involving in research. Paragraph 22, added in 2000, states in part: 
In any research on human beings, each potential subject must be 
adequately informed of the aims, methods, sources of funding, any 
possible conflicts of interest, institutional affiliations of the 
researcher, the anticipated benefits and potential risks of the study 
and the discomfort it may entail.24 
 
It is important to note, however, that the Declaration of Helsinki fails to include 
provisions necessitating or even recommending inclusion of female subjects, or mandating that 
research directives attend to gender-specific conditions, or address the differing affects of drugs 
on different sex or minority bodies. Because the Declaration excluded provisions requiring 
clinical studies to include females, the Declaration of Helsinki and its progeny set the stage for a 
series of international guidelines that failed to incorporate an appreciation for feminist concerns 
in clinical research.  
Without encouragement to include females in clinical drug development, international 
clinical discovery developed around the male form. The three leading nations of drug 
development, the U.S., U.K., and Japan, performed domestic drug trials with male participants.25 
As my introductory section outlined, clinical research scares of the 1950s and 1960s inspired 
protectionist legislation in both the U.S. and U.K.26 Japan similarly concluded that the hormonal 
fluctuations and reproductive capacity of females rendered them ill-suited for regulated clinical 
                                                 
23
 Id. at 651. 
24
 World Medical Assembly, DECLARATION OF HELSINKI: ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING 
HUMAN SUBJECTS, (18th ed. 2008) [hereinafter the Declaration of Helsinki]. 
25
 See, e.g., J.T. Fullerton, Issues in Clinical Trials Management; Women In Clinical Trials 1950–1993: From 
Exclusion to Equity. 49 RES NURS; 1, 8–10, 14–6 (1995). 
26
 See infra notes 7-9;  
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 participation.27 Legislatures responded to researchers who sought to limit their liability by 
passing regulations excluding pre-menopausal women from studies, justifying the effort as an 
attempt to avoid causing harm to as yet unborn children. Complementing these liability concerns, 
however, was the unfortunate reality that research in all three of these countries was conducted 
almost exclusively by men. The gender identity of those conducting and funding clinical research 
directly resulted in a clinical model designed, unintentionally, to accommodate the male 
experience in clinical research.28 This kind of bias precluded researchers from choosing to design 
trials that accounted for women’s experience in medicine,29 or at the administrative level, 
choosing to fund research accommodating women in research. 30 
Ultimately, the exclusionist model of clinical research went unchallenged for just a few 
decades. In the 1970s, women began to enter research and medicine.31 They began to articulate 
concerns for the discriminatory impact of exclusion of women in medical research, presenting 
                                                 
27
 Justin McCurry. Japan Unveils Plan to Boost Clinical Research. 369 LANCET: 1333, 1336 (2007). 
28
 See Carol Tavris, THE MISMEASURE OF WOMEN, 96-98 (1992) (explaining that, to this day, in global premier   
medical schools, students learn the anatomy and physiology of the 70-kilogram man: what his urine output is, what 
dosages of medication he should get, etc. A study reviewing eighteen leading anatomy texts used in medical schools 
found that identifiably male bodies and body parts constitute 64% of the illustrations, while female bodies were used 
only for 11% of the illustrations, except in the chapters on reproductive anatomy; see also Kay Weiss, What Medical 
Students Learn About Women, SEIZING OUR BODIES: THE POLITICS OF WOMEN’S HEATH 12-18 (Claudia Dreifus ed., 
1978) (from a gynecology text,”[Plredominantly male. . . researchers, policy makers, and practitioners. . . have 
typically dealt with differences among types of clients by placing everyone, except white middle-aged men, in 
special population categories. . . . This special population approach provides a way to incorporate data and 
experience that is inconsistent with general expectations…but reduces the need to examine and revise the 
fundamental assumptions that define the standard for normal . . . services); see also Rebecca Dresser, Wanted: 
Single, White Male for Medical Research, 22 HASTING CET. RP. 24, 28 (Jan.-Feb. 1992) (biomedical researchers 
define the white male as the normal, representative human being); see Ellen Goodman, A Health-Research Bias. 
BOSTON GLOBE. June 21.1990, at 15. (quoting Representative Patricia Schroeder, Congressional leader, "[Ylou fund 
what you fear. When you have a male-dominated group of researchers, they are more worried about prostate cancer 
than breast cancer.") 
29
 With respect to mental health and developmental research, the picture is much the same. 
See, e.g., Lindsay Van Gelder, The Importance of Being Eleven: Carol Gilligan Takes On Adolescence, MS., July-
Aug. 1990, at 77(quoting Carol Gilligin, "[T]he study of adolescence has been the study of males, in reference to the 
ongoing work of the Harvard University Project on the Psychology of Women and the Development of Girls); see 
also WOMEN AND DRUGS: A NEW ERA OF RESEARCH 489 (Barbara Ray & Monique Braude eds., 1986) ("The history 
of drug abuse research shares with other sciences a relative paucity of knowledge about females in particular and 
about gender effects in general. This bias in knowledge stems from the tradition of using male subjects for animal 
and human experiments and an unexamined assumption that gender is not an important experimental variable.") 
30
 See Scott Greenberger, Science Friction: The Struggle of Female Researchers at NIH, WASH. POST, July 
11,1993, at C3. (An internal task force convened in 1991 to assess the career development and status of women 
scientists at NIH. It found that women made up only 18% of the tenured scientists, although they constituted 30% of 
the last decade's post-docs (the traditional track to senior status). Extensive reports by female scientists of anti-
woman bias at NIH range from denial of lab time, and rejection of domestic and international project proposals. In 
1992, a Washington, D.C. television station ran a six-part investigative report that featured dozens of female NIH 
researchers alleging discriminatory treatment) 
31
 See Bernadine Healy, Women in Science: from Panes to Ceiling, SCIENCE 67 (1992). (Female first-year medical 
school enrollment steadily grew after the 1960s, from 4% in 1930, to 9% in 1969, to over 50% in 1990.) 
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 evidence the inclusion of women in clinical discovery was necessary to obtain important 
information about the efficacy of new drugs and interventions in both sexes.32 In 1986, the 
United State's National Institute of Health adopted a policy recommending the inclusion of 
women in clinical research. Responding to the recommendations of physician associations and 
the lobbying of women's groups, Congress adopted the NIH Revitalization Act, which required 
adequate numbers of women for valid analyses of differences related to phase 3 trials.33 The 
Food and Drug Administration (FDA) guidelines ended the restriction on women of child-
bearing potential in the early 1990s.34 
This shift in regulatory approach manifested on the international stage soon thereafter. In 
the 1980s, Europe, Japan and the United States initiated an attempt to harmonize international 
guidelines with their differing, respective national regulatory requirements, looking to the ethical 
principles of the Declaration and the International Ethical Guidelines as a baseline.35 At the 
WHO Conference of Drug Regulatory Authorities (ICDRA), in Paris, in 1989, specific plans for 
action between these three leading research nations began to materialize, and in April 1990, 
representatives of the regulatory agencies and industry associations of Europe, Japan and the US 
met to etch out a common legal framework for conducting clinical trials within their borders and 
regulating research in other countries. The International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) produced the 
first ICH Terms of Reference in 1990. Today, the ICH operates to achieve harmonisation among 
Europe, Japan and the US to ensure that safe, effective, and high quality medicines are developed 
and registered in the most resource-efficient manner.36 
 The ICH Guidelines were the first international standards to address the legal and ethical 
approach to inclusion of women in clinical research. The Guidelines addressed the dangers of 
drug therapies solely developed with the use of male subjects.37 ICH Guideline E8, for example, 
requires that a study population be representative of the target patient population, and 
specifically mandates that Phase I pharmacokinetic information in women be submitted for 
                                                 
32
 See infra note 26, 27. 
33
 M.N. Prout. Participation of women in clinical trials of drugs therapies: a context for the controversies. 3 MED 
GEN MED 60 (2001). 
34
 Id.  
35
 See supra, note 5. 
36
 Introductory comments to the ICH 20th Anniversary Publication. Found at http://www.ich.org/home.html.  
37
 Maria Teresa Ruiz Cantero & Maria Angeles Pardo. European Medicines Agency policies for clinical trials leave 
women unprotected. J EPIDEMIOL COMMUNITY HEALTH. 60 911: 911–913 (2006). 
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 regulatory approval.38 It further requires dose response data from relevant sub-populations, 
including categories according to gender. Guidelines E3 and M4E call for a characterization of 
the patient population, as well as analyses and critical assessment of the data with respect to 
sex.39 
Together, the Declaration of Helsinki and the ICH Guidelines stood as the most 
influential international doctrines defining rules for international clinical research. The ICH 
Guidelines, of course, were unfortunately only binding upon the U.S., U.K., and Japan. To 
supply guidelines and regulations for those countries non-party to the ICH, but participants in 
international research, the World Health Organization and the United Nations Educational, 
Scientific and Cultural and Organization (UNESCO) founded The Council for International 
Organizations of Medical Sciences (CIOMS) to prepare the International Ethical Guidelines for 
Biomedical Research Involving Human Subjects.40 
In the early 1980s, CIOMS began to compose a set of guidelines which could serve to 
guide the application of the ethical principles set forth in the Declaration of Helsinki in the 
construction and conduct of biomedical research; they were developed with particular concern 
for their application in developing countries, given the socioeconomic circumstances, laws and 
regulations, and executive and administrative arrangements in those nations.41 The outcome of 
the CIOMS/WHO undertaking was the Proposed International Ethical Guidelines for Biomedical 
Research Involving Human Subjects.42 The Ethical Guidelines used the principles outlined in the 
Declaration of Helsinki, those of beneficence, justice, and human dignity, to establish a set of 
rules and recommendations for international clinical research. The Guidelines hold,  
[t]hese three principles, which in the abstract have equal moral force, guide 
the conscientious preparation of proposals for scientific studies. In varying 
circumstances they may be expressed differently and given different moral 
weight, and their application may lead to different decisions or courses of 
                                                 
38
 International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH), ICH Guidelines. November 19, 2005. (Available online at 
http://www.ich.org/cache/compo/1.html (accessed April 21, 2011).  
39
 Id. 
40
 Goldfrab, supra note 13.  
41
 Temple R. Impact of the Declaration of Helsinki on Medical Research from a Regulatory Perspective. Address to 
the Scientific Session, World Medical Association General Assembly, September 2003.  
42
 World Health Organization (WHO) Council for International Organization of Medical Services (CIOMS) 
International Guidelines for Biomedical Research involving Human Subjects. Introductory Comments. Nov. 13, 
1982. [hereinafter Ethical Guidelines] 
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 action. The present guidelines are directed at the application of these 
principles to research involving human subjects.43 
 
The recommendations the CIOMS Ethical Guidelines lack an international body or 
mechanism serving as an enforcement apparatus. However, domestic governments, along with 
public and nonprofit entities, have developed legal and fiscal methods to bind clinical trial 
operations to the rules of clinical ethics set forth by international doctrines. Countries with 
leading research institutions and large government research programs have incorporated these 
doctrines into their domestic regulations, for trials conducted both within their borders and 
internationally with government funding.44  
The Council of Europe, with 44 Member States, developed a Protocol on Biomedical 
Research which mandates that physicians and researchers operating within the European Union 
adhere to CIOMS’s Ethical Guidelines.45 It further includes an enumerated Convention on 
Human Rights and Biomedicine.46 The Convention inspired the European Clinical Trial 
Directive in 2001, a doctrine adopting the spirit of the principles and provisions of the 
Declaration of Helsinki.47 This became binding on member states in 2004.48 It, too, made certain 
clinical practices of the Ethical Guidelines mandatory for all clinical drug trials performed by 
member states of the European Union.49 
 The United States enforces international guidelines through recommendations of the 
National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research, established by the National Research Act.50 The Commission issued a report in 1979 
(the Belmont Report) that serves as the basis for regulating all research, domestic and 
                                                 
43
 Ethical Guidelines, supra note 42 at 12.  
44
 E.J. Cassell. The principles of the Belmont report revisited. How have respect for persons, beneficence and justice 
been applied to clinical medicine? 30 HASTINGS CENT REP 12, 12–21. (2000). 
45
 Directive 1998/44/EC of the European Parliament and of the Council of Europe. (August 13, 1998). 
46
 Id. 
47
 European Parliament: Council on the Good Clinical Practice in the Conduct of Clinical Trials. Clinical Trials 
Directive, 2001/20/EC, April 4, 2001. With the Clinical Trials Directive, the European Union (EU) established a 
harmonisation of research ethics committees (RECs) across Europe, including the reporting requirements, 
requirements specific to the time taken to assess a trial proposal and the kinds of issues a committee should take into 
account.  
48 Directive 2001/20/EC of the European Parliament and of the Council of Europe (April 4, 2001). 
49
 Id. 
50
 Office for Protection from Research Risks, National Institutes of Health. Protecting Human Research Subjects: 
Institutional Review Board Guidebook. (1993). 
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 international, sponsored by the federal government.51 The Report directly adopted the principles 
articulated in the Declaration of Helsinki,52 espousing beneficence, justice, and human dignity. It 
provides a framework stemming from these principles to guide the resolution of ethical problems 
arising from research involving human subjects.53 In 1981, the Department of Health and Human 
Services (DHHS) and the Food and Drug Administration (FDA) issued regulations based on the 
Belmont Report. The FDA issued CFR Title 21 (food and drugs), Parts 50 (protection of human 
subjects) and 56 (Institutional Review Boards), and DHHS issued Code of Federal Regulations 
(CFR) Title 45 (public welfare), Part 46 (protection of human subjects).54 These regulations 
beget further regulations promulgated in the spirit of the principles of beneficence, justice, and 
human dignity.55  
In Japan, international clinical trials are strictly regulated by the Pharmaceutical Affairs 
Law and by the Ministry of Health, Labor and Welfare (MHLW) Ordinance on GCP, which was 
adopted in Japan in 1997.56 The Ordinance is based on the International Conference on 
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use 
(ICH) E6 Guidelines.57 The MHLW provides Ethical Guidelines for Clinical Studies, mimicking 
                                                 
51
 Department of Health, Education, and Welfare. NATIONAL COMMISSION FOR THE PROTECTION OF HUMAN 
SUBJECTS OF BIOMEDICAL AND BEHAVIORAL RESEARCH. Belmont Report: Ethical principles and Guidelines for the 
Protection of human subjects of Research. Washington (DC): May 20,1978 [herein after the Belmont Report] 
52
 The Belmont Report, supra note 39. (The expression ”basic ethical principles” refers to those general judgments 
that serve as a basic justification for the many particular ethical prescriptions and evaluations of human actions. 
Three basic principles, among those generally accepted in our cultural tradition, are particularly relevant to the 
ethics of research involving human subjects: the principles of respect of persons, beneficence and justice.)  
53
 Id. 
54
 The Food and Drug Administration. 21 C.F.R. 5 10.90(b) (1993) (research conducted in good faith pursuant to 
Guidelines will be accepted by FDA for review). See also 21 C.F.R. 8 312.145 (1993) ("A person may rely upon the 
Guidelines with assurance that it is acceptable to FDA.”) 
55
 In 1991, the core DHHS regulations (45 CFR Part 46, Subpart A) were formally adopted by more than a dozen 
other Departments and Agencies that conduct or fund research involving human subjects as the Federal Policy for 
the Protection of Human Subjects, or "Common Rule." In 1991, the Department of Veterans Affairs promulgated 
this same rule at 38 CFR Part 16. Today, the 1991 Federal Policy is shared by 17 Departments and Agencies, 
representing most, but not all, of the federal Departments and Agencies sponsoring human-subjects research. 
56
 H. Yanagawa, S. Abe. Clinical trials for drug approval: a pilot study of the view of doctors at Tokushima 
University Hospital. 53 J MED INVEST. 290, 292–296 (2006).  
57
 J. McCurry. Japan Unveils 5-year Plan to Boost Clinical Research. LANCET. 129, 133-136 (2007). (For example, 
Japan’s MHLW adopts the Ethical Guideline 13 directly, requiring that informed consent in international clinical 
work be obtained according to the legal requirements and cultural standards of the community in which the 
intervention is carried out. Within one week the physician must report to the ethical review committee the details of 
the case and the action taken, and an independent health-care professional must confirm in writing to the ethical 
review committee the treating physician's judgment that the use of the investigational intervention was justified 
according to the three specified criteria.) 
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 the guidelines of CIOMS, and establishes a set of ethical recommendations based on the 
principles of beneficence, justice, and human dignity.58  
In addition to domestic regulations, grant institutions and funding bodies have developed 
fiscal incentives to render the Ethical Guidelines de facto binding upon international research 
projects. Several of the most prestigious international and multinational organizations funding 
modern research work have issued ethical guidelines for clinical trials that adopt directly or 
mimic the Declaration of Helsinki’s standards.59 These funding bodies require all funded projects 
to abide by enumerated rules of ethics.60 These incentives work in tandem with those of domestic 
regulatory bodies to create de facto as well as actual enforcement mechanisms for international 
ethical guidelines.61  
The United Nations has led an effort that tracks and analyzes the effects of such 
regulatory and recommended guidelines on women’s experience in clinical discovery. In 1995, 
the United Nations convened the Fourth World Conference on Women in Beijing, China.62 
Delegates from the UN’s Member Nations prepared a Platform for Action;63 in the enumerations 
of the Platform, the Conference signaled a clear commitment to the progress of international 
norms and standards of equality between men and women, proclaiming that the “human rights of 
women and girl-children are an integral part of universal human rights and must underlie all 
action.”64 The Platform proceeded to outline a series of recommended actions to ameliorate 
gender parity; importantly, four of its recommendations specifically address women’s experience 
in health and heath research.65 Since 1995, the Conference has convened in five-year increments 
                                                 
58
 Id.  
59
 Griffin, supra note 9, at 430-433. (The U.N., one of the largest sources of funding for AIDS and infectious disease 
research worldwide, cannot enforce the guidelines legally, but requires their funded projects to abide the rules of the 
Declaration of Helsinki. Similarly, the World Health Organization requires their projects to abide by their 
established Guidelines for Good Clinical Practice for Trials on Pharmaceutical Products, and the International 
Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 
requires their grantees to follow the Guideline on Good Clinical Practice, which serve to ensure that data generated 
from clinical trials are mutually acceptable to regulatory authorities in the European Union, Japan and the United 
States of America. If countries refuse to follow or neglect certain provisions of these doctrines, funding bodies can 
revoke funding and disqualify organization or individual from subsequent consideration for research funding.)  
60
 See supra note 9, at 415. 
61
 Scot A. Fritzen. 83 Reorienting Health Ministry Roles: Capacity and Strategy Gaps. 83 HEALTH POLICY 73, 75 
(2007). 
62
 Report of the Fourth World Conference for Women: Beijing Declaration and Platform for Action. U.N. Doc. 
A/CONF.177/20/Rev.1. Sept. 15, 1995.  
63
 Id.  
64
 Id. at 12.  
65
 Id. at 27-29. (“Provide financial and institutional support for research on safe, effective, affordable and acceptable 
methods and technologies for the reproductive and sexual health of women and men, including more safe, effective, 
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 to assess international progression in relation to their recommendations; to date, UN Member 
States have provided three assessments of progress made.66 In 2000, 2005, and 2010, members of 
the Conference have reconvened to identify and analyze the remaining gaps and challenges in the 
implementation of the Platform for Action.67  Each convention year, regional commissions 
compose data for presentment, which provides the basis for analysis of trends and challenges in 
implementation of the Platform’s goals. Assessments of the Conference indicate that while the 
significant players on the global research stage have adopted legislation and funding protocols 
incentivizing adherence to specified ethical standards in research, regulatory bodies sometimes 
fall short of enforcing the regulations, or providing national standards for data and research 
results which appreciate women’s interests.68 Therefore, those performing research in certain 
                                                                                                                                                             
affordable and acceptable methods for the regulation of fertility, including natural family planning for both sexes, 
methods to protect against HIV/AIDS and other sexually transmitted diseases and simple and inexpensive methods 
of diagnosing such diseases, among others; this research needs to be guided at all stages by users and from the 
perspective of gender, particularly the perspective of women, and should be carried out in strict conformity with 
internationally accepted legal, ethical, medical and scientific standards for biomedical research;  a. Develop 
mechanisms to evaluate and disseminate available data and research findings to researchers, policy makers, health 
professionals and women's groups, among others; b. Monitor human genome and related genetic research from the 
perspective of women's health and disseminate information and results of studies conducted in accordance with 
accepted ethical standards.”)  
66
 See, Five Year Review of the Beijing Conference at a Special Session of the UN General Assembly (Beijing +5),  
Ten Year Review (Beijing +10)l Fifteen Year Review (Bejing+15) found online at 
http://www.un.org/womenwatch/confer/beijing/reports. 
67
 In addition to Member States and regional reports, the Conference draws upon a variety of sources of information 
and statistics to develop its findings, including reports submitted by States parties under the Convention on the 
Elimination of All Forms of Discrimination against Women; information generated in the context of the 
Commission on the Status of Women; regional action plans and national reports to regional bodies; as well as and 
the outcomes of expert group meetings and other activities at regional level. Other sources of information include 
Common Country Assessments and the United Nations Development Assistance Frameworks, (CCA/UNDAFs), 
Poverty Reduction Strategy Papers, (PRSPs), national Human Development Reports and national Millennium 
Development Goal (MDG) reports. (See supra note 61 at 2-3). 
68 See, e.g.  Report of the Economic and Social Commission of Asian and the Pacific, November 18, 2009, found 
online at http://www.un.org/womenwatch/daw/beijing15/regional_review.html . (The UN’s progression analysis 
shows improvement in some areas, but certain regulatory bodies need to improve in the Asian/Pacific region. During 
the twenty-third special session of the General Assembly in 2000, for example, the Conference’s Beijing +5 meeting 
presented the findings by five of the United Nations regional commissions (ECAP, ECE, ECLAC, ESCAP, 
ESCWA). The Economic Commission of Asia and the Pacific (ECAP) conceded in its report that efforts to obtain 
proper and accurate baseline data on the range of women's health needs was stifled by the lack of reported research 
trials, and blamed the regulatory bodies in Asian-Pacific countries for failing to enforce reporting rules. Id. at 2-4. 
Moreover, the report held that several governments were failing to develop reliable and valid indicators of women's 
health status. Id. at 5. Thailand’s government, for example, continued to rely on contraceptive prevalence rates, life 
expectancy of women and maternal mortality rates (when available) as sufficient health impact indicators to assess 
women's health needs. Id. Data available for South Korea, then, was comprised of primarily national data reflecting 
national averages. Id  at 14.The report acknowledged that it was difficult to obtain data which was already analyzed 
and presented by age, geographical location (rural, urban), class/income, religion/culture, indigenous and ethnic 
groups because research projects did not report many required descriptions of the participants in their trials. The lack 
of broadly available and reliable data made it difficult to develop an-depth approach to improving women's health 
on a regional level. For example, the Commission could not address targeted questions like which women were 
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 regions still are not properly incentivized to follow international ethical regulatory guidelines. 
The progressive conclusions have ultimately demonstrated that regulatory and fiscal mechanisms 
play an important and growing role in improving the feminist experience in research, but many 
national regulatory bodes must not only adopt international ethical standards, but also, strive to 
enforce regulatory measures in order to property incentivize adherence to doctrines like the 
International Ethical Guidelines.   
International efforts to improve women’s clinical experience provides true opportunities 
to effect change in the contemporary research model if they are endorsed by regulatory clinical 
bodies.  Since the turn of the millennium, international regulations have begun to shift away 
from protectionist policies. While maintaining adherence to the principles of beneficence, justice, 
and human dignity, for example, the ICH Guidelines and CIOMS’s International Ethical 
Guidelines for Biomedical Research Involving Human Subjects have catalyzed a gender-
inclusionary approach to clinical discovery.69 One of the most significant additions to the 
International Ethical Guidelines for Biomedical Research Involving Human Subjects occurred in 
2006. CIOMS issued a newly-amended Guideline 16, specifically addressing the inclusion of 
women in international research efforts.70  
Guideline 16 openly acknowledges that the former policy of excluding women from 
clinical trials was unjust in that it “deprives women as a class of persons of the benefits of the 
new knowledge derived from the trials.”71 It holds that such preclusion is an affront to their right 
of self-determination.72 The Guideline cautions that although women of child-bearing age should 
be given the opportunity to participate in research, they should be helped to understand that the 
research could include risks to the fetus if they become pregnant during the research.73 The 
Guideline acknowledges that women in clinical research face unique societal and cultural 
pressures complementing participation in trials.74 
However, while facially espousing feminist clinical principle leading international 
guidelines fail to present advice as to how practitioners or researchers may incorporate gendered 
                                                                                                                                                             
more at risk for acquiring cervical cancer and less likely to seek screening or treatment in many Asian countries, or 
which women are dying in pregnancy and childbirth, according to race, region, or age.) 
69
 See supra note 33, CIOMS Ethical Guidelines, at 3-5.  
70
 Id. 
71
 Id. at Commentary on Guideline 15.  
72
 Id. 
73
 Id. at 50-51. 
74
 Id.  
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 concerns into their procedures. Importantly, they lack advice as to how to acquire a feminist 
form of feminist informed consent in the process of conducting a clinical study on women. 
Moreover, these guidelines still lack attention to the question as to how rights of trial participants 
extend after their participation in a clinical effort. Currently, no international legislation requires 
that trial participants who dedicate their time and energies to drug discovery have access to the 
drugs after their personal trial participation ceases. In this next section, I explain how attention to 
these kinds of concerns can and should complement an ethical clinical trial that recognizes the 
human rights of women clinical participants.  
 
A Feminist Model of Clinical Research 
 Despite the ethical advances made in the past quarter century, past protectionist policies 
of law-makers and gender biases and liability considerations of the medical community have 
lingering effects, both in the design and regulation of contemporary clinical design. To this day, 
ethical considerations can still fall to the wayside in light of competing economic or efficiency 
interests.75 Though regulatory bodies in large nations have adopted and enforced international 
ethical guidelines, these institutions sometimes waiver in the face of countervailing market 
forces. In 2008, for example, the FDA announced that it was going to enforce the 1989 version, 
rather than the later, amended, versions, of the Declaration of Helsinki. 76 The change authorized 
pharmaceutical operations to run international clinical trials in which patients in the control 
group (i.e. those who are not getting the experimental drug) could be treated with placebos 
instead of the best standard medical care.77 The change has had important practical implications, 
                                                 
75
 Lionel D. Edwards, DESIGN AND CONDUCT OF RESEARCH IN WOMEN: TO INCLUDE OR EXCLUDE: A 
PHARMACEUTICAL INDUSTRY PHYSICIAN'S PERSPECTIVE 113-14 (1994) (In a confidential 1991 survey of 33 major 
pharmaceutical houses, conducted by the Pharmaceutical Manufacturers Association, 79% reported that FDA 
reviewers had required them to exclude women of child-bearing potential from their protocols.) 
76
 Dept. of Health and Human Services Food and Drug Administration. Human Subject Protection Foreign Clinical 
Studies Not Conducted Under an Investigational New Drug Application. 21 CFR 312. (2008) Published April 18, 
2008, effective October 27 2008. 
77
 See supra note 9, the Declaration of Helsinki, at paragraph 2a (states specific concepts with regard to the use of a 
control group: the benefits, risks, burdens, and effectiveness of the new methods should be tested against those of the 
best current prophylactic, diagnostic, and therapeutic methods. This does not exclude the use of placebo or no 
treatment in studies where no proven prophylactic, or therapeutic methods exist. In a Note of Clarification on 
paragraph 29, id, added in 2002, the Declaration notes, “extreme care must be taken in making use of a placebo 
control trial and that, in general, this methodology should only be used in the absence of existing proven therapy. 
However, a placebo controlled trial may be ethically acceptable, even if proven therapy is available, under the 
following circumstances: (a) where for compelling and scientifically sound methodological reasons its use is 
necessary to determine the efficacy or safety of a prophylactic, diagnostic, or therapeutic method; (b) where a 
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 considering that over a third of annual new drug applications the FDA reviews are the product of 
medical research performed overseas by for-profit Clinical Research Organizations (CROs).78 
Modern reality thus begs the question: can a modern clinical study be both legal, ethical and 
feminist at the same time? Can science feasibly aim to conduct clinical studies that respect the 
human rights of their female patients in light of competing market interests? What would patient 
and scientist participation look like in such a model? In this section and in the following case 
study, I explore these questions. 
Building from the central principles of the Declaration of Helsinki, 79 I propose that 
clinical research is ''ethical'' if it employs the principles of beneficence, justice, and human 
dignity while functioning with an understanding of the need to incorporate women's specific 
interests in medicine. This model will facilitate a woman's ability to make informed choices, 
exercise autonomy, and access the standard of care in medicine. This is an approach consistent 
with much of the commentary following Guideline 16 of the International Ethical Guidelines for 
Biomedical Research,80 but slightly improved. Guideline 16 categorically excludes pregnant or 
nursing women from trials unless the research carries no more than minimal risk for the fetus or 
infant.81 In the face of a trial objective to acquire new knowledge about pregnancy or lactation, 
however, women who are not pregnant or nursing would not be suitable subjects. This Guideline 
utterly ignores the right of pregnant or nursing women to make their own informed, personal 
risk-benefit calculus, while imposing no such restrictions on fertile and reproductively active 
male subjects. My clinical model utilizes a feminist, rather than a protectionist, approach to 
                                                                                                                                                             
prophylactic, diagnostic or therapeutic method is being investigated for a minor condition in the patients who receive 
placebo will not be subject to any additional risk of serious or irreversible harm.”)  
78
 See supra note 53, at part 312 (“The Food and Drug Administration (FDA) of the United States has ruled that 
clinical trials performed outside the US no longer have to conform to the Declaration of Helsinki if used to support 
applications for registration of products in the US. Instead, the International Conference on Harmonization Good 
Clinical Practice (GCP) has been designated as the new regulatory standard”); See also Normile D. Ethics. Clinical 
trials guidelines at odds with US policy. 322 SCIENCE 516 (2008). (“This suggestion met considerable opposition 
from scientists, ethicists, and consumer groups before and during the consultations. The FDA’s justifications 
included the arguments that it was merely harmonizing its regulations with a global standard, and that legal 
instruments, such as the US Code of Federal Regulations, cannot embed external documents subject to change 
beyond the agency’s control.”).  
79
 The Helsinki Declaration, supra note 19. (The Declaration proclaims, “Medical research is subject to ethical 
standards that promote respect for all human beings and protect their health and rights. Some research populations 
are vulnerable and need special protection. The particular needs of the economically and medically disadvantaged 
must be recognized. Special attention is also required for those who cannot give or refuse consent for themselves, 
for those who may be subject to giving consent under duress, for those who will not benefit personally from the 
research and for those for whom the research is combined with care.”) 
80
 See infra, notes 45-48. 
81
 Id. 
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 informed consent and participation. Using the insights of biologist and bio-ethicist Helen 
Beaquert, and human rights scholar K. Rajan, I apply a feminist lens to the interpretation and 
application of beneficence, justice, and human dignity to propose a model for an inclusionary, 
feminist clinical model. 
The principle of beneficence (i.e.,“do not harm”) dictates that all research participants be 
protected from the foreseeable risks (e.g., physical, psychological, social, or economic) involved 
in participating in the study of an untested or unproved therapy.82 Participants in a research study 
cannot be exposed to situations for which they have not been prepared or otherwise subjected to 
exploitation.83 Similarly, the principle of beneficence holds that women cannot be confined to 
drug therapies which may do them harm without information as to the extent or nature of these 
harms.84 Ultimately, the concept provides that the women of society should be protected from a 
loss of information that could only be gained by the participation of women in studies relevant to 
their safety and well-being. To protect from flawed or insufficient medical information, women 
should be incorporated proportionally into research trials, and should not be mandated to rely on 
solely male-representative medical findings. This includes trials of pregnable, pre-menopausal, 
lactating, and even pregnant, women85. 
Analyzing recent trends in international research, clinical trials often fail to incorporate 
the principle of beneficence in such a way, and neglect the significant of gender-balanced 
information to women's health. A study funded in 2007 by the American Heart Association 
revealed that in 156 randomized clinical trials performed over the three past decades by the 
United States, the U.K., Japan, Canada, Australia, and New Zealand, women’s participation has 
been markedly lower than that of males. Until the late 1980s, only 9 percent of clinical 
participants in these trials, concentrated on issues of heart and lung disease, were women. By 
                                                 
82
 The Belmont Report, supra note 39; See also, J. Fullerton, Ethical Considerations Related to the Inclusion of 
Women in Clinical Trials, 49 J MIDWIFERY & WOMEN’S HEALTH, 194, 201–202 (2004).  
83
 Id. at 196. 
84
 Id. at 197. 
85
 See,e.g. Dept. of Health Education and Welfare. National Commission for the Protection of Humans Subjects in 
Biomedical and Behavioral Research. Pub. No. 76-127: RESEARCH OF THE FETUS. 65 (1975) (“Therapeutic research 
directed toward the pregnant woman may expose the fetus to risk for the benefit of another subject and thus is at first 
glance more problematic. Recognizing the woman's priority regarding her own health care, however, the 
Commission concludes that such research is ethically acceptable provided that the woman has been fully informed 
of the possible impact on the fetus and that other general requirements have been met. Protection for the fetus is 
further provided by requiring that research put the fetus at minimum risk consistent with the provision of health care 
for the woman. Moreover, therapeutic research directed toward the pregnant woman frequently benefits the fetus, 
though it need not necessarily do so. In view of the woman's right to privacy regarding her own health care, the 
Commission concludes that the informed consent of the woman is both necessary and sufficient.”) 
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 2006, about a third of clinical trials participants were female, but in secondary prevention trials, 
females were only participating at a rate of 24.6 percent. Female enrollment was comparable in 
government/foundation-funded versus industry-funded trials (31.9% versus 31.5%), but the 
representation of women was consistently low for trials involving heart failure (29%), coronary 
artery disease (25%), and hyperlipidemia (28%). By contrast, women account for 53% of all 
individuals with hypertension, 50% with diabetes, 51% with heart failure, 49% with 
hyperlipidemia, and 46% with coronary artery disease in the world.86  
The study demonstrates that while enrollment of women in internationally conducted 
clinical trials has increased in recent decades, women's participation remains low relative to their 
overall representation in disease populations. More efforts are needed to reach a level of 
representation that is adequate to ensure evidence-based, sex-specific recommendations. Women 
must receive health care information at the same level and depth of their male counterparts, in 
each condition and stage of their reproductive lives, so as to not suffer from the absence of 
gender-specific information. 
The principle of justice includes the rights to equal access, full information, privacy, and 
respect for cultural and other forms of diversity. In the context of a feminist model of clinical 
research, this principle would require that everyone in society have equal opportunity to share in 
the benefits of newly emerging therapies. This principle acts along with the tenets of beneficence 
to dictate that society is served best when sufficient information is available about both sexes. 
Additionally, however, the principle of justice serves as the foundation for arguably the most 
fundamental concept embraced by major international doctrines concerned with drug discovery 
today: informed consent.  
Informed consent is meant to guarantee the voluntary nature of participation in research 
studies. Because clinical trial agreements are legal documents, much of their content necessarily 
has a legal flavor to it. The medical community once treated a patient's informed consent to be 
something like a contract at the beginning of a trial, something to be read and discussed, and then 
completed with a signature. 87 In a feminist, ethical model of clinical discovery, however, 
informed consent should develop a more sophisticated meaning. Explained by biologist and 
human rights scholar Helen Beaquert, a feminist construction of informed consent should 
                                                 
86
 Chiara Melloni, Representation of Women in Randomized Clinical Trials of Cardiovascular Disease Prevention. 3 
CARDIO OUTCOMES 135, 135-142 (2009).  
87
 T.L. Beauchamp, CONTEMPORARY ISSUES IN BIOETHICS. 98 (2nd ed. 1982.) 
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 manifest as an ethical state of a study rather then a static commencement agreement signed into a 
legal contract.88 A full consent on behalf of a volunteer comes as she learns and processes the 
key facts about a clinical trial; she is explained the terms, commitments, benefits and dangers in 
a straightforward way, in a language accessible for her understanding.89 90 
This form of consent gives a volunteer deliberation time before deciding whether or not 
to participate, and then once committed, promises that the providers of a contract will ensure that 
a woman’s body is provided for and never denied known preventative or successful curative 
therapies. This form of consent implies full knowledge and a clinician’s commitment to caring 
for a woman while under study, requiring all tests that inform clinicians of known potential 
dangers of a drug are performed. This type of full, informed contract of consent dictates that a 
clinician is ready to provide information for subjects at their request, or when trial conditions 
change, throughout a trial. 
Unfortunately, international clinical trials today often wield a less sophisticated 
understanding of informed consent. In 1991, for example, a team of independent research 
ethicists in Sweden performed an unannounced series of follow-up studies on clinical trials 
performed in that country over the prior three years. They meant to determine whether the 
participants in Sweden’s clinical trials had received adequate information about the trial 
according to the guidelines of the Declaration of Helsinki. Among the studies they reviewed, 
they targeted one sex-specific gynecological study for an investigation as to the quality of 
information given to its female participants. Of the 68 patients in the study, 43 women 
volunteered to participate in its follow-up review. The ethics committee determined that although 
the patients should have been consulted both orally and in writing when approached and when 
consent was sought, half the participants had received only oral information to establish their 
                                                 
88
 Helen Bequaert Holmes. Rights over One's Own Body: A Woman-Affirming Health Care Policy, 3 HUMAN 
RIGHTS QUARTERLY, 74, 71-87 (1981).  
89
 Id. at 76 
90
 This is particularly important for women in developing countries. See, e.g., CIOMS: Commentaries on Informed 
Consent, Guideline 4, supra note 33 at 16. (In some populations the use of a number of local languages may 
complicate the communication of information to potential subjects and the ability of an investigator to ensure that 
they truly understand it. Many people in extra-Western cultures are unfamiliar with, or do not readily understand, 
scientific concepts such as those of placebo or randomization. To appreciate this disparate understanding, CIOMS 
International Ethical Guidelines requires sponsors and investigators to develop culturally appropriate ways to 
communicate information that is necessary for adherence to the standard required in the informed consent process. 
The Guidelines further recommend that they should describe and justify in the research protocol the procedure they 
plan to use in communicating information to subjects. For collaborative research in developing countries the 
research project should, if necessary, include the provision of resources to ensure that informed consent can indeed 
be obtained legitimately within different linguistic and cultural settings.) 
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 informed consent for the purposes of the trial. Only 35 women answered that they remembered 
giving consent; others could not remember, or stated they had not consented. One woman 
revealed that she had never received any information and that she had been unaware of her 
participation in a research project until she received the ethicists’ follow-up questionnaire. At 
least 17 out of 43 women had not been aware that they could change their mind about 
participation, and, even more seriously, 15 out of 43 had not been aware that one of their two 
operations had been performed purely for scientific reasons. They had never received the written 
information, prepared by the trial’s directors, that the second look operation was of no medical 
advantage to them, and they were not informed orally. So, 15 women were motivated in their 
decision to participate by the possibility of receiving treatment, and participated under a deluded 
perception that the second operation was helping them.91 
In contrast to such evidence of discrepancies in past clinical discovery, a feminist model 
of clinical ethics would require that participants receive adequate information concerning the 
project's aims, methods, expected benefits, and potential hazards and discomforts, at its 
commencement, and then, at each stage in its progression.92 Furthermore, experimental subjects 
should be informed that they can abstain from participation in the study and are free to withdraw 
their participation at any time, without any risk with regard to the quality of the ordinary 
treatment.93 Provided that the participant understands the importance of the information and is 
fully capable of making a decision, informed consent can be obtained.  
In research involving women of reproductive age, whether pregnant or non-pregnant, a 
feminist model would require only the informed consent of the woman herself. However, in 
respecting the cultural nuances of transnational clinical trials, the model would hold that if 
women wish to consult with their husbands or partners or seek voluntarily to obtain their 
permission before deciding to enroll in research, that is not only ethically permissible but in 
some contexts highly desirable.94 Finally, a feminist consent discussion should include 
information about the alternatives of voluntarily withdrawing from the study, and requires that 
consent discussions be consistent throughout the course of a study.95 
                                                 
91
 Niels Lynoe, Mikael Sandlund, & Lars Jacobsson, Informed consent: Study of Quality of Information Given to 
Participants in a Clinical trial. 303 BMJ 14, 18 (1991). 
92
 See supra note 33, CIOMS Ethical Guidelines, at 48.  
93
 Id. at 50 
94
 Id.  at 49-50. 
95
 Id. 
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 The final principle underscoring a feminist, clinical effort is that of respect for human 
dignity. This incorporates the concepts of the right to self-determination and autonomy, and 
appreciates a component of access.96 This principle requires due diligence on behalf of clinical 
researchers to avoid implicit or explicit attempts to coerce a woman to participate in a study. 
Coercion can take the form of implicit or explicit threats of penalties for failure to agree to 
participate or for wishing to withdraw from participation. It can also take the form of excessive 
monetary or other personal reward (e.g., monetary compensation that is disproportionate to 
personal income) in exchange for study participation. Countries adopt this principle in varying 
ways. In Member States of the European Union, for example, regulatory authorities enforce laws 
forbidding incentives or financial inducements for minors or incapacitated adults unable to give 
consent.97 Spain forbids participation stipends, permitting compensation only to working minors 
and targeted vulnerable subjects.98 
A respect for human dignity, moreover, mandates that a clinical participant is treated as a 
human being, rather than quantified as a body in a clinical endeavor. Clinical trials require 
experimental subjects. However, the very epistemology of clinical trials is risk-laden—both for 
the subjects experimented upon, and for the research agents who invest huge amounts of money 
in a therapeutic molecule that may or may not eventually come to market. A form of structural 
violence of clinical experimentation emerges from the reality that it is a process that can only be 
set in motion by the risking of human subjects, and that clinical subjects are often incentivized 
by the promise of new, emerging therapies.99 The model stands, then, to encourage the 
experimental subject to make her body available for experimentation, but then is rendered 
incapable of drug access after the trial concludes, even after a therapy's approval.100 
An ethical clinical, trial, however, respects the need for access to therapy during a trial, 
and then, provides for such therapy following a trial's successful completion. This component of 
a feminist model can be informed by the theories of bio-ethicist Kaushik Sunder Rajan. 
According to Rajan, the common avenue for any sort of therapeutic access to experimental drugs 
is too often limited to ‘compassionate use’ programs of pharmaceutical companies, which make 
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 the drugs tested in Phase III trials available to the sick volunteers for a fixed period of time after 
completion of the trial.101 No regulatory body involved in developing clinical-practice guidelines 
insists that drugs tested in underdeveloped regions of the world should be marketed there.102 
‘Ethics’ in the distribution realm are provisional.  
The uncoupling of experimental subjectivity from therapeutic access enrolls experimental 
subjects in the cause of health, offers them agency, but locates them outside a regime of long-
term quality care.103 In other words, some experimental subjects contribute in a significant sense 
to health by making themselves available as experimental subjects, but this is in no way linked to 
their own healthiness, or that of others in their class who might obtain access to new medication 
as a consequence of the risks to which the volunteers are exposed. In these cases, in which high-
risk experimental subjectivity lacks potential for clinical benefit, the clinical testing model is 
inherently limited in design. A complete feminist model of clinical study incorporates 
beneficence and justice first, ensuring the consent of its subjects, but then, just as importantly, it 
ensures that clinical participation benefits volunteers.  
Clinical trials invariably take the form of a social contract in which a small number of 
people are put on potentially risky medication for the sake of a larger social good—the 
development of new therapies.104 However, those recruited into Phase 1 trials tend to be less 
well-off in comparison to those ultimately allowed access to the therapy, so that the social 
contract can never be a pure liberal one between groups of individuals.105 Ultimately, even if all 
clinical trials conducted in developing countries adhered to the letter of the law and the spirit of 
ethical codes, the very structure of this trial would remain one of exploitation.106 Too often, 
underdeveloped populations are used purely as experimental subjects, without the implicit social 
contract of eventual therapeutic access. In practice, there is no guarantee that an experimental 
drug tested on a local population will necessarily be marketed there after approval, let alone be 
made available at an affordable cost. However, in the event of successful development, a 
feminist, ethical trial model requires that the developed therapy will be accessible to its clinical 
participant group upon introduction to society. The requirement manifests first as access via the 
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 market; then, encourages research companies to opens forums for affordable, perhaps subsidized, 
access to a therapy to its subjects post-trial completion and approval.107 
This type of model-driven market access infrequently occurs in the modern era. In 2002, 
for example, a study of more than 15,000 people in Uganda demonstrated ignorance of such 
ethical concerns. The study concluded that the risk of spreading AIDS through heterosexual sex 
rose and fell with the amount of virus present in the blood. The research was controversial not 
because of its conclusions, but because of its methodology. Unlike studies of HIV in developed 
countries, the volunteers in Uganda were not offered treatment, nor did doctors advise or provide 
preventative measures to the healthy spouse of an infected partner harboring the virus. The team 
merely tracked infected individuals and their partners from October of 1994 to 1998, examining 
the relationship between serum viral load, concurrent sexually transmitted diseases, and other 
known HIV risk factors. Ultimately, Quinn and colleagues determined that targeted therapies 
aimed at specifically decreasing vial load in serum could prove promising as HIV/AIDS therapy, 
but then, failed to offer the group they had targeted any method of access these therapies, or any 
other kind of intervention, in their lifetimes. Those who participated in the study never received 
any, especially low-cost, means to treat their conditions; moreover, doctors and aids neglected to 
ever advise preventative measures to decrease rates of transmission to uninfected partners or 
future offspring.52  
The trial demonstrates just how voluntary research may manifest as unethical even when 
retaining elements of informed consent. Both of the study's groups had initially agreed to be 
volunteers in clinical research. In Uganda, doctors never lied or misled these subjects. But they 
failed to offer any kind of access to the HIV/AIDS therapies on the market or in development. 
The example demonstrates that when clinical research is successful but lacks either one of the 
key components of a feminist model, it fails to treat its subjects with feminist, ethical 
consideration.  
 
Case Study: The Oral Contraceptive 
This part of my paper presents an answer to the series of questions I presented earlier: can 
a clinical trial be both ethical, legal, and feminist? And importantly, can a feminist, ethical trial 
be fiscally as well as ethically successful? To demonstrate that a feminist model of clinical 
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 research efforts can lead to successful, marketable developments, I analyze a case study of a 
clinical trial which incorporated a feminist understanding of an ethical trial into its clinical 
model, and then successfully marketed its clinical findings. This case study critiques the early 
trials of the oral contraceptive pill. Using the feminist model I constructed above, emphasizing 
women's needs for agency and access in clinical work, I demonstrate that the clinical trials of the 
first birth control pill employed standards set forth by modern international standards of research 
while incorporating components regarding agency, informed consent, and access of my 
constructed feminist model. It can be used today as a model for ethical, clinical research.  
After giving some historical background, I organize my discussion into two components. 
The first component argues that the Puerto Rican women purposefully lived their clinical 
experience as partners with, and not tools of, the drug developers; they were aware of the 
dangers and benefits of their choices and acted with informed choice, and not coercion. The 
second component argues that, although the contraceptive trials progressed with the help of 
females from a comparatively developing country, these women and the groups they represented 
benefited from the ultimate drug design, and thus, were agents who contributed significantly to 
an effort which served their own interests.  
  
A. Historical Background 
When Gregory Pincus, the ''father'' of the birth control pill, decided to meet the challenge 
of finding a hormonal contraceptive, he entered unknown territory. Although chemists had begun 
to synthesize a number of compounds which appeared to have contraceptive qualities in the early 
1950s, no one knew how to anticipate the effects these chemicals might have on the female body, 
or whether they would cause adverse reactions. The only way to find out was to test the pill on 
women themselves. The task was expensive, socially charged, and logistically daunting; it 
required the aid of numerous researchers and, most importantly, female volunteers.  
Although initial theoretical and laboratory work was performed with a small group in 
Massachusetts, large-scale human study was made impossible in the United States by strict legal 
barriers of the era. As late as 1960, the American legal system was not hospitable to the idea of 
birth control. Thirty states had statutes prohibiting or restricting the sale and advertisement of 
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 contraception.108 The driving force behind the original anti-birth control statutes was a New 
Yorker named Anthony Comstock. Comstock, a devout Christian, began supplying the police 
with information for raids on sex trade merchants in the 1890s and came to political prominence 
with an anti-obscenity crusade. He soon identified the contraceptive industry as one of his 
targets. Comstock was certain that the availability of contraceptives alone promoted lust and 
lewdness.109 He supplied Congress with an anti-contraceptive proposal he drafted himself; within 
three years, U.S. legislation at the federal and state levels rendered contraceptive drug design 
punishable by law Collectively known as the Comstock Laws, a total of twenty-seven pieces of 
legislation served as strong legal obstacles to the experimentation with and clinical association to 
contraceptive distribution or research. They prohibited the publication of any material associated 
with birth control, outlawed distribution of contraceptive means, and set heavy fiscal and 
punitive penalties on those who conducted research in the area.110  
Katherine McCormick financed the first years of the drug’s development and the initial 
drug studies. She was a woman devoted to the idea of finding a contraceptive method safe and 
available for all women everywhere, and was specifically determined to help further the idea of a 
affordable oral contraceptive which might be consumed in private to render a woman 
temporarily infertile.111 For McCormick, it was imperative to find a simple control that was 
divorced from coitus, ideally a contraceptive pill which women could swallow at any time 
without a man's knowledge. She saw as the key to women's empowerment.112 Despite her own 
eagerness to see the fruits of the project, she conveyed in correspondence a key understanding 
that both she and the team she financed, shared:  
Human females are not rabbits in cages. The latter can be 
intensively controlled all the time, whereas the human females 
leave town at unexpected times, cannot be examined due to time 
constraints, they forget or dislike to take medications—in which 
case, we must start all again over at once. Scientific accuracy must 
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 be maintained or the resulting data is worthless; in short, we need 
the full cooperation of our women.113 
 
From the start, the researchers knew they needed to conduct such trials outside of 
Massachusetts because of the Comstock laws. In that state, those found breaking the Comstock 
laws faced penalties of up to five years in prison and fines of $1,000 on each occasion that 
contraceptive inquiry and devices were provided or developed.114 Various possibilities were 
discussed; New York, Puerto Rico, Japan, Hawaii, India, and Mexico were each strongly 
considered. Puerto Rico was ultimately favored because directors of the University of Puerto 
Rico Medical School were trained in America, and Pincus expected them to conduct tests on 
vaginal tissue samples, endometrial biopsies and urine analyses in the same manner as his 
American team. Just as importantly, Puerto Rico was near enough to the US to enable close 
supervision by Pincus and his team, as the study’s primary investigators.115  
   
 
B. A Feminist Model I: Women Exercising Agency as Study Subjects 
Ultimately, the first large-scale field studies were mounted in Puerto Rico in April of 
1956.116 While researchers considered Puerto Rico ideal for the tests primarily for its proximate 
location and its cooperative and similarly trained staff, the island was fitting for a number of 
other reasons. It already possessed a thriving family planning movement and well-established 
network of birth control clinics. As early as 1935, private humanitarian groups were advancing 
financial aid from the United States to start birth control in Puerto Rico.117 An American-trained 
clinician concerned with the public health of his island, Dr. Clarence J. Gamble, along with a few 
affluent Puerto Ricans, organized and funded the Maternal and Infant Health Association in 
January, 1937, and opened twenty-two birth-control clinics in that country in fourteen months.118 
The government of Puerto Rico supported their effort; on May 15, 1937, the Legislative 
Assembly of Puerto Rico authorized the Commissioner of Health to:  
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 ...[I]ssue a license to teach and practice eugenic principles in public 
institutions and centers, to physicians who are specialists in 
obstetrics, or to physicians who are not specialists, and to midwife 
nurses who pass an examination or who comply with the regulations 
prescribed for the purpose.119  
 
The Commissioner could thereafter authorize persons to teach birth-control methods and 
distribute contraceptives to both married couples and those who "publicly live in concubinage." 
The 1937 laws dealing with birth control and abortion were readily signed by Acting Governor 
Menendez Ramos, who stated,  
I hope that the Insular Government will take active part in the 
dissemination of such information [modern birth control methods]. I 
think maternal clinics should be set up in all the large population 
centers of the island.120 
 
In Puerto Rico's governing bodies, poverty and shortages of food and housing trumped 
the Catholic identity of the island. For two decades prior to the pill's trials, for example, the 
Puerto Rican Secretaries of Agriculture and Development directed funding for birth control 
clinics across the island in an attempt to manage the island’s population growth, trying to address 
the food shortages and severe poverty that wrecked the island in the 1940s and 50s and that were 
strained further by an ever-growing populace.121  
This was the climate in which Pincus and his team began to test improved contraceptive 
measures, and it was this growing population and chronic poverty that predisposed the women of 
Puerto Rico to be open to new birth control methods despite that fact that many were faithful to a 
Catholic identity.122 The women themselves came from various classes and backgrounds, and did 
not possess uniform training or educational identities. Some were teachers, others were nurses; 
many were secretaries and still more worked as saleswomen and traders. They comprised a 
model which demonstrated that the pill could be used by a diverse group of women in terms of 
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 education and occupation, from those who lacked medical training to those who lacked formal 
schooling altogether.123  
The trials demanded a high degree of effort and cooperation. The trial volunteers had to 
be willing to commit to several months of complicated lifestyle rules and intense scrutiny, 
climaxing in a series of surgical interventions.124 Failure to comply would present significant 
data lapses to the clinical study. So, during these trials, researchers instructed women to follow 
very complicated and time-consuming routines. Besides being required to take hormone tablets, 
each woman had to take her own body temperature readings and vaginal smears on a daily 
basis.125 Every woman also had to collect urine once a week for an entire day to be given to the 
researchers for hormone analysis.126 This procedure was particularly burdensome: it required a 
woman to be within easy reach of a toilet and special collection and analysis supplies. In 
addition, a third of the participants had to consent a monthly endometrial biopsy.127 These 
biopsies involved taking a tissue sample from the womb lining, a procedure which is at best 
uncomfortable and at worst extremely painful. Some women were given laporatomies (open 
abdominal surgery to observe directly ovarian and uterine changes) on the twenty-third day of 
their cycles. All of these cumbersome procedures were designed to determine whether the 
compound effectively suppressed ovulation, and therefore had contraceptive potential.128 As 
Katherine McCormick wrote to trial co-sponsor Margaret Sanger in June of 1954,  
I find incredulous the headache of these tests and the cooperation of 
the women patients...there is so much (testing) and it must be 
accurate. I really do not know how it is obtained at all—it is so 
onerous, it really is—these women attend so carefully, however, and 
so persistently.”129 
 
In later correspondence, McCormick marvels at the women of Puerto Rico, detailing 
incidents in which she visited sites with Rock to see women asking questions about their side 
effects and asking permission to take anti-nausea or pain relief medicine in conjunction with 
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 their contraceptive pills. She admires one woman's dedication in having her literate grade-school 
daughter help her record daily dosages and meticulously count out the requisite five rest days 
between pill cycles.130  
The twenty-member research team encouraged this active participation, instructing 
women from the start to bring all concerns and questions to the doctors’ attention and helping 
them to understand the practices mandated by their participation in the trials. Each woman’s 
consent and understanding was carefully acquired. At the commencement of the trials, each of 
the trial’s requirements was explained, in English or through local translators.131 Women had to 
agree to the procedures, and before obtaining new pills, had to agree and give willing consent 
again. The early trials in Puerto Rico did not involve signed forms of consent, but as Dr. Lugli 
Mastroianni, a member of the ground team, recalled later in the 1980s,  
The concept of informed consent that is so talked about now, and 
is a legal requirement of any research project involving human 
volunteers today, didn't exist then [during the oral contraceptive 
trials]. But Rock practiced it before it was even defined. There 
were...long discussions of the risk factors with each volunteer, 
and we were told to welcome both their feedback and their 
concerns, any time during the trials. It didn't matter that Rock 
had no formal guidelines, he set his own—they were high 
standards indeed.132 
 
As Mastroianni indicates, the regulatory bodies which are today responsible for ensuring 
ethical clinical protocol did not exist in the 1950s. “Informed consent” was a term, in fact, that 
was not yet coined. However, the oral contraceptive trials were characterized by a theory of 
informed consent that could meet the international standards of today, and serve as example of 
the kind of consent to achieve in a feminist, ethical trial setting. The trial’s model required that 
participants receive adequate information concerning the project's aims, methods, expected 
benefits, and potential hazards and discomforts, at its commencement, and then, at each stage in 
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 its progression.133 Furthermore, each of the woman subjects was informed that they were free to 
withdraw their participation at any time, without any risk.134 Rock and his researchers explained 
the terms, commitments, benefits and dangers in a straightforward way to these participants, in a 
language accessible to the Puerto Rican women. They provided that each participant understood 
the importance of the information and was fully capable of making a decision. The oral 
contraceptive trial set-up gave each volunteer deliberation time before deciding whether or not to 
participate, and then provided information for subjects at their request, or when trial conditions 
change, throughout a trial. Each month, every woman had the opportunity to cease participation. 
 Rock's ethical concerns were mirrored in the conduct of the man who led the team of 
researchers in Puerto Rico. Though legally unnecessary, Celso Ramon Garcia similarly strove to 
execute a project with the full consent and commitment of his participants.135 Garcia was 
particularly concerned with the medical side effects and yet-unknown consequences of taking the 
pill. Therefore, he insisted that certain tests be performed on the patients during the trials, such as 
investigations for liver functioning, Pap smears, and tests for blood clotting.136 These 
investigative tests became increasingly important for both the women and the researchers, 
catching negative side-effects early, especially as time went on and the scientists learned about 
the dangerous effects, like blood clotting and stroke, incident to higher dosages.137 His approach 
lent the women’s consent a more sophisticated meaning. Garcia approached a trial in such a way 
as to treat consent as an ethical state of a study rather then a static commencement agreement; his 
regular physicals ensured that each participant was kept abreast of the health impacts from her 
participation in the study.138  
In the age of the pill's development, before the dawn of international ethical guidelines 
and modern regulatory agencies, clinical trials generally lacked thorough attempts of careful 
oversight.139 Garcia's actions, however, were born of a personal sense of responsibility—he 
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 reveals in an interview that he felt a duty to ''ensure good health care'' for the women in the trials 
in Puerto Rico.140 He describes that many of the trial participants lacked access to quality health 
care services outside of the trial, and were often side effects like dizziness and nausea.141 He 
further describes that he developed a special concern for the drug's potential ability to damage 
reproductive functions, or cause infertility.142 As a result, he determined it clinically appropriate 
to require his team to perform physicals and medical examinations on the trial subjects at least 
twice a month.143  
The trial's success with constructing ethical, feminist forms of consent and 
communication is also reflected by the deference with which the scientists treated the 
participant’s self-reports.144 Their technical data sets were supplemented by the woman’s 
voices.145 Throughout the early months of the pill’s testing, clinicians relied on testimony of the 
four hundred women during on-going consent discussions to steer reconfiguration of the pill’s 
drug make-up. Pincus later held that the trial process would not have evolved but for the 
researchers’ incorporation of women's reports.146 They highlighted initial problems of nausea; 
then, sporadic breakthrough bleeding and headaches; finally, dizziness, changes in blood 
pressure and odd pains—complaints that inspired clinical suspicion of increased potential for 
blood clotting.147 Candid reports of such conditions led to changing amounts of the synthetic 
hormones in the pill.148 The subjects’ testimony was thorough because their consent and 
authentic cooperation had been sought and then maintained.  
Over four hundred Puerto Rican women participated in the first drug trial of the oral 
contraceptive. Several of the women were coping with large families of small children; they took 
time from busy lives of myriad responsibilities to travel long distances and keep painstaking 
records of their experiences on the pill. Women came to the project in an effort to control this 
aspect of their lives. As one subject, Julia, explains,  
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 I am thirty, have ten children, aged sixteen to ten months. My 
husband is very ill, drinks heavily and makes life difficult. I do odd 
jobs to support the family, and me and my husband do [have daily 
intercourse] but he won’t let me use contraception. I’ve been using 
this medicine a whole year, and got through the whole year….with no 
baby!149 
 
 
Ultimately, the clinical model in Puerto Rico provided its participants the opportunity to 
secure full information, at every stage during their experience, in a beneficent way. The pill's 
clinical research team considered women’s unique bodies and understanding within scientific 
discourse, and treated the patients involved in their medicine as partners rather than passive 
witnesses. Theirs was an ethical, feminist approach to clinical practice, one allowing their 
women participants to make fully informed choices amidst the multidimensional concerns of 
their lives. The leaders of the research established the procedures and rules of their trial in such a 
way as to have the researchers themselves and the clinicians on the ground available to the 
subjects throughout the trial, answering questions, attending to problems, and providing medical 
assistance with diligence. In behaving in such an accessible manner, maintaining a dialogue with 
subjects ensuring informed consent, the clinical directors embodied an ethical approach to the 
trial that would satisfy that of a feminist model of clinical ethics. 
The evidence of informed consent and ethical clinical practice does not singularly support 
my claim that these trails were conducted with components of a feminist clinical approach. 
Importantly, as I argue next, this practice of securing informed consent was complemented by 
the trial’s component of access.  
 
C. A Feminist Model II: Women Reaping Fruits of their Labor 
Moving from evidence of informed consent and agency among the female participants 
involved with the pill's testing, I will now argue that the contraceptive trials followed an ethical 
model in that the pill was a drug that benefited those who participated in the furthering of the 
pill's research.   
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 In general, research agendas reflect the interests, power, and privilege of the elites who 
set them; they are seldom defined by the health needs or interests of those who are most 
marginalized in society.150 These kinds of clinical studies produce knowledge that strengthens 
the health and opportunity of those who are already well placed in society, and often ignore the 
needs of the disadvantaged. Clinical participants are often granted access to therapies during 
clinical discovery trials, for example, and then precluded from accessing therapies once they are 
reviewed and marketed.151  
The clinical trails of Puerto Rico, in contrast, allowed for ready access to the birth control 
pill: the country's underdeveloped populations were not used purely as experimental subjects. 
After the drug's regulatory approval, the women were granted therapeutic access to the first 
contraceptive drug available. In practice, the researchers did not personally distribute pills to 
individual clinical participants; however, the pharmaceutical company with whom the 
researchers contracted to develop and market the pill, Searle, worked with the researchers to 
direct the pill back to Puerto Rico.152 The pill, then, was accessible to the female participants of 
the contraceptive studies, and to the other women of the country.  
Part of the reason the drug developers could direct the pill's market distribution to 
facilitate participant assess lay in the nature of its niche therapeutic use. Enovid passed the 
FDA’s tests on June 17, 1958,153 and, in the jargon of the industry, was advertised as an “ethical 
specialty:” it was advertised to doctors and sold in prescriptions, not directly to the general 
public.154 Though it was not advertised directly to customers, doctors like Pincus, Rock, and 
Garcia had a great deal of leverage as to which physicians, including those operating in the 
subsidized birth control clinics of Puerto Rico,155 could be convinced to proscribe the drug 
initially.  The pill’s researchers, then, responded to their trial participant’s needs for access to 
therapy after their trial, providing for the therapy following a trial's successful completion. This 
kind of physician-based distribution ensured that the therapeutic access to experimental drugs 
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 wasn’t limited to a ‘compassionate use’ program, either, which would have made the drugs 
available to the volunteers for a fixed period of time after completion of the trial.156  
A key element of the clinical participant's access opportunities lay in the fact that half of 
the expense of pill proscriptions was borne by the Department of Health of the Commonwealth 
of Puerto Rico.157 This distribution of funding was directed away from governmental subsidizing 
of the foam contraceptive called Emko, a contraceptive then determined to be only 70 percent 
effective.158 So in terms of Puerto Rico's capacity to provide birth control to those seeking it, a 
newly appropriated annual funding of $500,000 per clinic in 1958 lowered a patient's monthly 
costs to less than 25 percent of market expense, or a third of a day's median wages for the 
average 30-yr-old female in Puerto Rico in 1959.159  In addition, the government sponsored an 
information campaign for the pill. Handbills, comic books, pamphlets, and a newsletter titled 
"The Right to Happiness" were distributed across the island.160  
The readers of Puerto Rico were reached through such materials. For those who could not 
read and knew no one who could, the government sponsored civic group-run community forums, 
where respected community groups brought together the spokesmen of clinics and sometimes the 
government's Department of Health in familiar community spaces, responding to residents of the 
community during question-and-answer sessions.161 After adjusting for population numbers, the 
women of Puerto Rico used the pill in proportional numbers to the women, both white and black, 
of America in the years following its market release.162 
Ultimately, the trials of Puerto Rico became rather widely publicized, mostly by anti-
contraceptive groups.163 Thousands of women in the United States and Europe, aware of the 
trials and the FDA deliberation, impatiently waited for the chance to try it. Upon approval in the 
U.S. and Britain, after continued, successful use in Puerto Rico, it quickly arrived in Haiti, Latin 
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 American nations, Copenhagen, and Japan.164 Family planning clinics and doctors alike had 
access to the pill and readily distributed prescriptions. Interestingly, limitations to access were 
never found in comparatively poor or developing economies. The places with the greatest access 
challenges were those rich with conservative values, like the American states of Kentucky and 
South Dakota.165  
The oral contraceptive trials were characterized by the complete feminist model of 
clinical study. The trials incorporated beneficence, human dignity, and justice, ensuring the 
consent of trial subjects, and just as importantly, ensuring that clinical participation benefited the 
female volunteer participants. The uncoupling of experimental subjectivity from the subsequent 
therapeutic access of the oral contraceptive offered the clinical participants a chance to 
contribute in a significant sense to their health by making themselves available as experimental 
subjects, and linked this participation to their own long-term benefit, and that of others in their 
community who might obtain access to new medication as a consequence of the risks to which 
the volunteers and their families were exposed. The feminist model design of the trial 
demonstrates that ethics, regulations, and market initiatives can combine in a feminist 
framework, and that successful drug therapies can result from international clinical discovery 
that allows their women to experience all the elements of a feminist, ethical clinical model. 
 
Conclusion and Recommendations 
A woman coming into the health care system is a unique individual psychologically and 
physically. Every aspect of her health and well-being should be acknowledged, and her 
contributions to the discourse around her clinical participation, through both concerns and 
positive feedback, should be incorporated in a model of her health interests. An ethical, feminist 
research model that upholds the modern ethical standards of international clinical discovery 
should further be characterized by a negotiation between subjects and investigators that 
maintains full and informed consent methods, and ensure that subject groups ultimately benefit 
from access to a treatment's scientific inquiry.  
When analyzing the clinical trials of the pill in Puerto Rico with this model, the clinical-
research landscape demonstrates that a model can be ethical while feminist, and ultimately, a 
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 successful marketing endeavor. The oral contraceptive pill is and always has been an 
indisputable clinical goldmine: at any given moment, over 100 million women worldwide are 
using the oral contraception, and the average user takes the pill for almost twelve years of her 
life.166 
Looking forward to future international clinical endeavors, I propose two specific 
recommendations to augment the contemporary guidelines for international clinical drug 
development. Regulatory bodies of nations should require those seeking market approval for new 
drugs and treatment methods to utilize a feminist clinical model, and adopt funding protocols 
incentivizing adherence to specified ethical standards in research. Using legal and fiscal 
incentives, international clinical endeavors should promote an ethical, feminist experience, 
allowing for, specifically, components of true consent and therapy access.  
Regulatory bodes should require that trial developers construct and implement a process 
for consent that addresses women's information needs and questions at the commencement of 
trials, and in addition, incorporate supplemental consent discussions at periodic times during a 
trial. These consent discussions should invite a woman's specific feedback explaining her 
experience in the trial endeavor and encourage women to express developing concerns with any 
element of the trial or clinical experience. While treating women within the feminist, ethical 
framework, these conversations further the success of clinical trials as they allow clinical 
researchers to obtain important information about the efficacy of new drugs and interventions in 
the context of women’s physiology. With such knowledge, researchers can design therapies that 
respond to women’s specific needs and thus allow women to derive equal benefits from the 
scientific discovery process. 
Regulatory bodies should also encourage scientific researchers to facilitate access to drug 
therapies post-clinical development and approval.  Women who dedicate their bodies and their 
experiences to clinical discovery must be allowed access to the therapies they forward. Without 
this opportunity, women’s bodies are quantified as tools of experiments, rather than valued in the 
way that international ethics guidelines dictate, that is, according to the principles of beneficence, 
justice, and human dignity. Ultimately, I recommend that the next stage in the progressive 
development of international clinical regulation should be to promulgate feminist considerations 
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 in clinical efforts, ensuring informed consent and a participant's access to therapies after clinical 
participation.  
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